Janssen Pharmaceuticals Inc.’s efforts to staunch the flow of its price concessions under the 340B program contributed to a relatively small decline in the discounts in 2022 – from $6.4bn in 2021 to $6.2bn – according to the company’s recently released US pricing transparency report for the year.
Key Takeaways
-
Janssen's 340B discounts totaled $6.2bn in 2022, down from $6.4bn in 2021.
But the 340B program remained the second largest recipient of Janssen’s price concessions in the US, representing 16% of all...